Single patient access to itacitinib for STAT1 GOF disease
Treatments studied
Part of Immune system & allergy clinical trials.
This trial provides access to a drug called itacitinib for a single patient with a rare genetic immune disease (STAT1 GOF). It may help reduce inflammation and other symptoms caused by the overactive immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific genetic condition called STAT1 gain-of-function (GOF) disease.
- Your doctor agrees this treatment is appropriate for you.
- You have not responded to or can't use other available treatments.
- You are willing to receive an experimental drug through a special program for individual patients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a pill called upadacitinib (a JAK inhibitor) for people with certain gene changes that cause an overactive immune system. The goal is to see if the drug can help control immune-related symptoms.
This trial tests whether tofacitinib, a pill that calms the immune system, can help people whose heart inflammation caused by cancer immunotherapy (called ICI) is not improving with steroid treatment. It may offer a new option for those with this rare but serious side effect.
This trial tests whether the drug tofacitinib can help people with ALS by calming an overactive immune system. You’ll need a genetic test to see if your immune profile matches what the study is looking for.
This Phase 2 study tests itacitinib, a targeted medicine, to see if it can safely improve diffuse systemic sclerosis (a hardening/tightening of the skin and organ involvement). You may be eligible if you have active disease or it has been present less than 3 years.
This trial tests a medicine called upadacitinib (an anti-JAK pill) for people with giant cell arteritis that affects the large arteries, especially the aorta. It is for those whose disease is active despite trying another treatment called tocilizumab, and aims to reduce inflammation and prevent damage.
This trial tests whether a new medication called gecacitinib can prevent a common complication after a stem cell transplant for myelofibrosis. The complication, called graft-versus-host disease, happens when donor cells attack the patient's body. The drug is given before and after the transplant.
Hear when a new STAT1 Gain-of-Function Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.